Why the study?
The long-term safety and effectiveness of home monitoring of implantable cardioverter defibrillators compared with ambulatory follow-ups needed prospective evaluation.
Does home monitoring of implantable cardioverter defibrillators reduce major adverse events compared to standard ambulatory follow-ups in patients with ICDs?
Does home monitoring of implantable cardioverter defibrillators reduce major adverse events compared to standard ambulatory follow-ups in patients with ICDs?
Home monitoring of ICDs is non-inferior to standard ambulatory follow-up for major adverse events and significantly reduces the number of appropriate and inappropriate shocks while sparing battery life.
Answers are grounded in this paper and cite their sources.
Home monitoring may safely reduce in-person ICD visits; confirms non-inferiority and extends remote care evidence in RCTs.
AIMS: The ECOST trial examined prospectively the long-term safety and effectiveness of home monitoring (HM) of implantable cardioverter defibrillators (ICD). METHODS AND RESULTS: The trial's primary objective was to randomly compare the proportions of patients experiencing ≥ 1 major adverse event (MAE), including deaths from all causes, and cardiovascular, procedure-related, and device-related MAE associated with HM (active group) vs. ambulatory follow-ups (control group) in a sample of 433 patients. The 221 patients assigned to the active group were seen once a year, unless HM reported an ICD dysfunction or a clinical event requiring an ambulatory visit, while the 212 patients in the control group underwent ambulatory visits every 6 months. The characteristics of the study groups were similar. Over a follow-up of 24.2 months, 38.5% of patients in the active and 41.5% in the control group experienced ≥ 1 MAE (P < 0.05 for non-inferiority). The overall number of shocks delivered was significantly lower in the active (n = 193) than in the control (n = 657) group (P < 0.05) and the proportion of patients who received inappropriate shocks was 52% lower in the active (n = 11) than in the control (n = 22) group (P < 0.05). At the end of the follow-up, the battery longevity was longer in the active group because of a lower number of capacitor charges (499 vs. 2081). CONCLUSION: Our observations indicate that long-term HM of ICD is at least as safe as standard ambulatory follow-ups with respect to a broad spectrum of MAE. It also lowered significantly the number of appropriate and inappropriate shocks delivered, and spared the device battery. Clinical trials registration NCT00989417.
No takes yet. Share an insight, caveat, or question.
Guédon-Moreau et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: